Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 1.25
BRKR's Cash to Debt is ranked higher than
63% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.82 vs. BRKR: 1.25 )
BRKR' s 10-Year Cash to Debt Range
Min: 0.13   Max: No Debt
Current: 1.25

Equity to Asset 0.42
BRKR's Equity to Asset is ranked higher than
60% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.64 vs. BRKR: 0.42 )
BRKR' s 10-Year Equity to Asset Range
Min: 0.14   Max: 0.69
Current: 0.42

0.14
0.69
Interest Coverage 11.06
BRKR's Interest Coverage is ranked higher than
56% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 94.07 vs. BRKR: 11.06 )
BRKR' s 10-Year Interest Coverage Range
Min: 0.71   Max: 9999.99
Current: 11.06

0.71
9999.99
F-Score: 6
Z-Score: 3.46
M-Score: -2.83
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 6.58
BRKR's Operating margin (%) is ranked higher than
80% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.61 vs. BRKR: 6.58 )
BRKR' s 10-Year Operating margin (%) Range
Min: -3.71   Max: 13.34
Current: 6.58

-3.71
13.34
Net-margin (%) 3.55
BRKR's Net-margin (%) is ranked higher than
79% of the 256 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.20 vs. BRKR: 3.55 )
BRKR' s 10-Year Net-margin (%) Range
Min: -6.73   Max: 9.58
Current: 3.55

-6.73
9.58
ROE (%) 7.88
BRKR's ROE (%) is ranked higher than
79% of the 233 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. BRKR: 7.88 )
BRKR' s 10-Year ROE (%) Range
Min: -9.05   Max: 23.93
Current: 7.88

-9.05
23.93
ROA (%) 3.33
BRKR's ROA (%) is ranked higher than
80% of the 261 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.22 vs. BRKR: 3.33 )
BRKR' s 10-Year ROA (%) Range
Min: -5.06   Max: 11.34
Current: 3.33

-5.06
11.34
ROC (Joel Greenblatt) (%) 18.48
BRKR's ROC (Joel Greenblatt) (%) is ranked higher than
82% of the 260 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.02 vs. BRKR: 18.48 )
BRKR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6.11   Max: 51.88
Current: 18.48

-6.11
51.88
Revenue Growth (3Y)(%) 11.50
BRKR's Revenue Growth (3Y)(%) is ranked higher than
88% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. BRKR: 11.50 )
BRKR' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 22.8
Current: 11.5

0
22.8
EBITDA Growth (3Y)(%) 0.60
BRKR's EBITDA Growth (3Y)(%) is ranked higher than
74% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. BRKR: 0.60 )
BRKR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 153.7
Current: 0.6

0
153.7
EPS Growth (3Y)(%) -6.10
BRKR's EPS Growth (3Y)(%) is ranked higher than
72% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.30 vs. BRKR: -6.10 )
BRKR' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 57.4
Current: -6.1

0
57.4
» BRKR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

BRKR Guru Trades in Q4 2013

NWQ Managers 1,136,005 sh (+415.25%)
Murray Stahl 26,618 sh (+61.03%)
Jim Simons 534,010 sh (+31.98%)
Pioneer Investments 177,836 sh (+31.55%)
Vanguard Health Care Fund 3,285,758 sh (unchged)
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
» More
Q1 2014

BRKR Guru Trades in Q1 2014

Steven Cohen 17,278 sh (New)
Joel Greenblatt 94,974 sh (New)
Pioneer Investments 287,632 sh (+61.74%)
Murray Stahl 33,965 sh (+27.6%)
NWQ Managers 1,207,030 sh (+6.25%)
Vanguard Health Care Fund 3,285,758 sh (unchged)
Jim Simons 450,210 sh (-15.69%)
» More
Q2 2014

BRKR Guru Trades in Q2 2014

Louis Moore Bacon 190,000 sh (New)
Paul Tudor Jones 27,571 sh (New)
Joel Greenblatt 898,448 sh (+845.99%)
Pioneer Investments 344,237 sh (+19.68%)
NWQ Managers 1,211,209 sh (+0.35%)
Vanguard Health Care Fund 3,285,758 sh (unchged)
Murray Stahl 32,993 sh (-2.86%)
Jim Simons 259,110 sh (-42.45%)
» More
Q3 2014

BRKR Guru Trades in Q3 2014

Joel Greenblatt 1,440,516 sh (+60.33%)
Murray Stahl 43,262 sh (+31.12%)
Paul Tudor Jones 32,794 sh (+18.94%)
Pioneer Investments 387,897 sh (+12.68%)
NWQ Managers 1,312,031 sh (+8.32%)
Vanguard Health Care Fund 3,285,758 sh (unchged)
Louis Moore Bacon Sold Out
Jim Simons 255,960 sh (-1.22%)
» More
» Details

Insider Trades

Latest Guru Trades with BRKR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-09-30 Add 60.33%0.1%$18.56 - $24.56 $ 19.56-8%1440516
Joel Greenblatt 2014-06-30 Add 845.99%0.24%$20.03 - $24.45 $ 19.56-10%898448
Joel Greenblatt 2014-03-31 New Buy0.03%$19.07 - $24.25 $ 19.56-10%94974
NWQ Managers 2013-12-31 Add 415.25%0.16%$18.56 - $21.23 $ 19.560%1136005
NWQ Managers 2013-09-30 New Buy0.04%$15.91 - $20.99 $ 19.562%220478
Joel Greenblatt 2013-09-30 Sold Out 0.02%$15.91 - $20.99 $ 19.562%0
Vanguard Health Care Fund 2013-06-30 Add 307.28%0.14%$15.94 - $19.13 $ 19.5613%3285758
Vanguard Health Care Fund 2013-03-31 New Buy0.06%$15.238 - $19.1 $ 19.5612%806758
Joel Greenblatt 2012-12-31 Reduce -84.28%0.18%$11.77 - $15.54 $ 19.5642%38498
Joel Greenblatt 2012-09-30 New Buy0.21%$11.34 - $14.13 $ 19.5654%244897
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 50.30
BRKR's P/E(ttm) is ranked higher than
81% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BRKR: 50.30 )
BRKR' s 10-Year P/E(ttm) Range
Min: 7.15   Max: 107.17
Current: 50.3

7.15
107.17
P/B 4.10
BRKR's P/B is ranked higher than
73% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.46 vs. BRKR: 4.10 )
BRKR' s 10-Year P/B Range
Min: 1.32   Max: 8.89
Current: 4.1

1.32
8.89
P/S 1.80
BRKR's P/S is ranked higher than
84% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.17 vs. BRKR: 1.80 )
BRKR' s 10-Year P/S Range
Min: 0.5   Max: 2.55
Current: 1.8

0.5
2.55
PFCF 23.50
BRKR's PFCF is ranked higher than
89% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BRKR: 23.50 )
BRKR' s 10-Year PFCF Range
Min: 9.23   Max: 159.85
Current: 23.5

9.23
159.85
EV-to-EBIT 26.37
BRKR's EV-to-EBIT is ranked higher than
82% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BRKR: 26.37 )
BRKR' s 10-Year EV-to-EBIT Range
Min: -101.5   Max: 82
Current: 26.37

-101.5
82
PEG 12.55
BRKR's PEG is ranked higher than
87% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BRKR: 12.55 )
BRKR' s 10-Year PEG Range
Min: 0.29   Max: 56.9
Current: 12.55

0.29
56.9
Shiller P/E 38.20
BRKR's Shiller P/E is ranked higher than
91% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BRKR: 38.20 )
BRKR' s 10-Year Shiller P/E Range
Min: 20.11   Max: 339.33
Current: 38.2

20.11
339.33
Current Ratio 2.29
BRKR's Current Ratio is ranked higher than
68% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. BRKR: 2.29 )
BRKR' s 10-Year Current Ratio Range
Min: 1.26   Max: 4.99
Current: 2.29

1.26
4.99
Quick Ratio 1.37
BRKR's Quick Ratio is ranked higher than
60% of the 257 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. BRKR: 1.37 )
BRKR' s 10-Year Quick Ratio Range
Min: 0.43   Max: 3.95
Current: 1.37

0.43
3.95

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 5.63
BRKR's Price/Tangible Book is ranked higher than
77% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.25 vs. BRKR: 5.63 )
BRKR' s 10-Year Price/Tangible Book Range
Min: 1.35   Max: 20.45
Current: 5.63

1.35
20.45
Price/DCF (Projected) 1.95
BRKR's Price/DCF (Projected) is ranked higher than
89% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BRKR: 1.95 )
BRKR' s 10-Year Price/DCF (Projected) Range
Min: 0.9   Max: 11.13
Current: 1.95

0.9
11.13
Price/Median PS Value 1.05
BRKR's Price/Median PS Value is ranked higher than
81% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.36 vs. BRKR: 1.05 )
BRKR' s 10-Year Price/Median PS Value Range
Min: 0.35   Max: 17.4
Current: 1.05

0.35
17.4
Price/Graham Number 3.46
BRKR's Price/Graham Number is ranked higher than
85% of the 282 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BRKR: 3.46 )
BRKR' s 10-Year Price/Graham Number Range
Min: 1.07   Max: 17.07
Current: 3.46

1.07
17.07
Earnings Yield (Greenblatt) 3.80
BRKR's Earnings Yield (Greenblatt) is ranked higher than
81% of the 254 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.00 vs. BRKR: 3.80 )
BRKR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.2   Max: 17.9
Current: 3.8

1.2
17.9
Forward Rate of Return (Yacktman) 3.35
BRKR's Forward Rate of Return (Yacktman) is ranked higher than
64% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.28 vs. BRKR: 3.35 )
BRKR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -5.6   Max: 88.9
Current: 3.35

-5.6
88.9

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:A, ROP, GRMN, HXGBY, TRMB » details
Traded in other countries:BKD.Germany,
Bruker Corp is a designer and manufacturer of proprietary life science and materials research systems and associated products that address the rapidly evolving needs of customers in life science, pharmaceutical, biotechnological, clinical and molecular diagnostics research, and materials and chemical analysis in various industries and government applications. Its technology platforms include magnetic resonance technologies, mass spectrometry technologies, gas chromatography technologies, X-ray technologies, spark-optical emission spectroscopy, atomic force microscopy, stylus and optical metrology technology, and infrared and Raman molecular spectroscopy technologies. Company manufacture and distribute a broad range of field analytical systems for chemical, biological, radiological, nuclear and explosives, or CBRNE, detection. It also design, manufacture and market high and low temperature superconducting materials and devices based on metallic low temperature superconductors. The Company is organized into four operating segments: the Bruker BioSpin Group, the Bruker CALID Group, the Bruker MAT Group, and Bruker Energy & Supercon Technologies division. The Bruker BioSpin Group combines the Bruker Magnetic Resonance and Preclinical Imaging divisions and designs, manufactures and distributes enabling life science tools based on magnetic resonance and preclinical imaging technologies. The Bruker CALID Group combines the Bruker Life Sciences and Clinical, Bruker Chemical and Applied Markets, Bruker Detection and Bruker Optics divisions. It designs, manufactures and distributes life science mass spectrometry instruments that can be integrated and used along with other sample preparation or chromatography instruments, as well as Chemical, Biological, Radiological, Nuclear and Explosive detection products and instruments based on Raman molecular spectroscopy technologies. The Bruker MAT Group combines the Bruker AXS, Bruker Nano Surfaces, Bruker Nano Analytics and Bruker Elemental divisions and designs, manufactures and distributes spectroscopy and microscopy instruments for the analysis of composition and structure in material science and life science samples. The Bruker Energy & Supercon Technologies division develops and produces low temperature superconductor and high temperature superconductor materials for use in advanced magnet technology and energy applications as well as linear accelerators, accelerator cavities, insertion devices, other accelerator components and specialty superconducting magnets for physics and energy research and a variety of other scientific applications. Company maintains direct sales forces throughout North America, Europe, Japan, Asia Pacific and Australia. It also utilizes indirect sales channels to reach customers. It also has various international distributors, independent sales representatives, and various other representatives in parts of Asia, Latin America, and Eastern Europe. Company have broad an
» More Articles for BRKR

Headlines

Articles On GuruFocus.com
comment on BRKR Mar 23 2013 
Weekly CEO Buys Highlight: NGL, BRKR, UTHR, KTOS, GBL Dec 24 2012 
Bruker BioSciences Corp. (BRKR) CEO Frank H Laukien buys 10,000 Shares Mar 17 2011 
Bruker BioSciences Corp. (BRKR) CEO Frank H Laukien buys 1,220 Shares Mar 03 2011 
Weekly CEO Buys Highlight: Deer Consumer Products, Dynex Capital, Bruker BioSciences Corp, American Mar 27 2010 
Weekly CEO Buys Highlight: Bruker BioSciences Corp, Dynex Capital Inc, American Dairy Inc, Pioneer D Mar 21 2010 
Bruker BioSciences Corp. (BRKR) CEO Frank H Laukien buys 100,000 Shares Mar 18 2010 
Bruker BioSciences Corp. (BRKR) CEO Frank H Laukien buys 100,000 Shares Mar 15 2010 
Bruker BioSciences Corp. (BRKR) CEO Frank H Laukien buys 3,570 Shares Dec 15 2009 
Weekly CEO Buy Highlights: Bruker BioSciences Corp, Cousins Properties Inc, FIFTH STREET FINANCE, La Sep 27 2009 

More From Other Websites
Bruker to Pay $2.4 Million to Resolve FCPA Charges Dec 15 2014
BRUKER CORP Files SEC form 8-K, Other Events Dec 15 2014
Bruker to pay $2.4 mln to settle US SEC charges over bribery Dec 15 2014
Bruker Introduces BioScope Resolve High-Resolution BioAFM System Dec 15 2014
Bruker Introduces BioScope Resolve High-Resolution BioAFM System Dec 15 2014
Bruker Introduces UMT TriboLab for Unmatched Material Testing Functionality and Modularity Dec 01 2014
Bruker Enters High-Performance NanoIndenting Market, Launches NanoForce Nanomechanical Testing... Dec 01 2014
Bruker Introduces UMT TriboLab for Unmatched Material Testing Functionality and Modularity Dec 01 2014
BRUKER CORP Files SEC form 8-K, Change in Directors or Principal Officers Nov 17 2014
Bruker Downgraded to Sell on Disappointing Q3 Outcome Nov 14 2014
BRUKER CORP Financials Nov 14 2014
Bruker (BRKR) Downgraded From Buy to Hold Nov 12 2014
Bruker DE-tector™ Explosives Trace Detector Meets New European Civil Aviation Conference (ECAC)... Nov 10 2014
Bruker DE-tector™ Explosives Trace Detector Meets New European Civil Aviation Conference (ECAC)... Nov 10 2014
10-Q for Bruker Corp. Nov 09 2014
Another lackluster session for major equities Nov 07 2014
BRUKER CORP Files SEC form 10-Q, Quarterly Report Nov 07 2014
Bruker misses Street 3Q forecasts Nov 06 2014
Bruker misses Street 3Q forecasts Nov 06 2014
BRUKER CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Nov 06 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK